Design: Prospective, randomized, crossover, experimental trial with a two-week washout period.
Animals:Six adult healthy cats weighing 4.6 ± 0.7 kg.Methods: Cats were sedated with 36 -56 µg kg -1 dexmedetomidine and received a retrobulbar injection of 0.5 % bupivacaine (0.75 mL; 3.75 mg) and iopamidol (0.25 mL), or peribulbar injection of 0.5 % bupivacaine (1.5 mL; 7.5 mg), iopamidol (0.5 mL), and 0.9 % saline (1 mL) via a dorsomedial approach. Blood was sampled (2 mL) before, and at 5, 10, 15, 22, 30, 45, 60, 120, 240, and 480 minutes after bupivacaine injection. Atipamezole was administered approximately 40 minutes after bupivacaine injection. Plasma bupivacaine and 3-hydroxybupivacaine concentrations were determined using liquid chromatography/mass spectrometry.Bupivacaine maximum plasma concentration (Cmax) and time to Cmax were determined from the data.
Results:The bupivacaine median (range) Cmax, and time to Cmax were 1.4 (0.9 -2.5), and 1.7(1.0 -2.4) µg mL -1 , and 17 (4 -60), and 28 (8 -49) minutes, for retrobulbar and peribulbar injections respectively. In both treatments the 3-hydroxy-bupivacaine peak concentration was 0.05 -0.21 µg mL -1 .
Conclusion:In healthy cats, at a dose up to 2 mg kg -1 , the bupivacaine peak plasma concentration was approximately half that reported to cause arrhythmias or convulsive EEG in cats, and about one sixth of that required to produce hypotension (Chadwick 1985, de Jong et al. 1982.